Back

Spyre Therapeutics analyst maintains Buy rating with $115 price target

Verifying
  • Wells Fargo analyst Yanan Zhu maintained a Buy rating on Spyre Therapeutics.
  • $115 was Zhu’s price target after shares closed at $93.19.
  • Spyre reported a $36.2 million quarterly GAAP net loss ending June 30.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.